Amneal Pharmaceuticals Inc. Earnings Dividend

Amneal Pharmaceuticals Inc.’s net profit jumped 539.61% since last year same period to $78Mn in the Q1 2026. On a quarterly growth basis, Amneal Pharmaceuticals Inc. has generated 122.37% jump in its net profits since last 3-months.

Amneal Pharmaceuticals Inc.’s price-to-earnings ratio after this Q1 2026 earnings stands at 58.32.

Amneal Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.19 - a 7.53% jump from last quarter’s estimates.

Amneal Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.19.

Amneal Pharmaceuticals Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Amneal Pharmaceuticals Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Amneal Pharmaceuticals Inc.’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Amneal Pharmaceuticals Inc.’s return on equity (ROE) stands at -8.81.